Cullinan Therapeutics, Inc. CGEM Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Cullinan Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Cullinan Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cullinan Therapeutics, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cullinan Therapeutics, Inc.'s operating cash flow?
- Cullinan Therapeutics, Inc. (CGEM) reported operating cash flow of -$46.05M in Q1 2026.
- How has Cullinan Therapeutics, Inc.'s operating cash flow changed year-over-year?
- Cullinan Therapeutics, Inc.'s operating cash flow decreased by 6.7% year-over-year, from -$43.16M to -$46.05M.
- What is the long-term trend for Cullinan Therapeutics, Inc.'s operating cash flow?
- Over 4 years (2021 to 2025), Cullinan Therapeutics, Inc.'s operating cash flow has grown at a 41.8% compound annual growth rate (CAGR), from -$43.43M to -$175.75M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.